Company profile
Medite Cancer Diagnostics, Inc.
OTC: MDIT · Healthcare · Medical - Instruments & Supplies
#677 of 1,422 Healthcare companies by revenue26th-percentile growth
EA Score
——FH —DQ —GM —SS 54
v0.1 · 5/100 weight · pillars only
↑ listing tenure, workforce scale · ↓ market scale, disclosure history
Methodology →Revenue TTM
$6.8M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$6.8M
Employees
69
as of 2026-08-03
Market cap
$8.7k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.8M$6.8M2017
Net income-$6.8M-$6.8M2017
Operating income-$6.5M-$6.5M2017
Total assets$16.0M$16.0M2017
Liabilities$10.2M$10.2M2017
Equity$5.8M$5.8M2017
Revenue trend
FY2015 – FY2017 · USD
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Medite Cancer Diagnostics, Inc.’s revenue?
Medite Cancer Diagnostics, Inc. booked $6.8M in FY2017 revenue, contracting 26% year over year — slower than 74% of Healthcare companies we track, at a -100.0% net margin.
Peers · Healthcare
Whitehawk Therapeutics Inc50DImmunome, Inc.47DINVO Fertility, Inc.43DReliq Health Technologies Inc.——Pacific Health Care Organization, Inc.74BFate Therapeutics, Inc.43DNeighbors
Orange →Key facts
CEORahsan-Rahsan Lindsay
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersOrlando, FL
ExchangeOTC: MDIT
Employees69
IPO date1995-02-01
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.